These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2504619)

  • 1. In vitro and in vivo characterization of a high-purity, solvent/detergent-treated factor VIII concentrate: evidence for its therapeutic efficacy in von Willebrand's disease.
    Mazurier C; De Romeuf C; Parquet-Gernez A; Goudemand M
    Eur J Haematol; 1989 Jul; 43(1):7-14. PubMed ID: 2504619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial.
    Mannucci PM; Tenconi PM; Castaman G; Rodeghiero F
    Blood; 1992 Jun; 79(12):3130-7. PubMed ID: 1596562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
    Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
    Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
    Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
    Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
    Aihara M; Kimura A; Chiba Y; Yoshida Y
    Thromb Haemost; 1988 Jun; 59(3):485-90. PubMed ID: 3142084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III.
    Lethagen S; Berntorp E; Nilsson IM
    Ann Hematol; 1992 Dec; 65(6):253-9. PubMed ID: 1457586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of von Willebrand's disease. A comparative study of diagnostic tests on nine families with von Willebrand's disease and its differential diagnosis from hemophilia and thrombocytopathy.
    Lian EC; Deykin D
    Am J Med; 1976 Mar; 60(3):344-56. PubMed ID: 1083143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of a very-high-purity, solvent/detergent-treated, von Willebrand factor concentrate.
    Mazurier C; Jorieux S; de Romeuf C; Samor B; Goudemand M
    Vox Sang; 1991; 61(1):1-7. PubMed ID: 1949703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
    Escolar G; Carretero M; Magallón M; Quintana M; Arnau C; Castillo R; Aznar-Salatti J
    Haematologica; 1998 Nov; 83(11):1009-14. PubMed ID: 9864923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet adhesion to collagen in subtypes of type I von Willebrand's disease is dependent on platelet von Willebrand factor.
    d'Alessio P; Zwaginga JJ; de Boer HC; Federici AB; Rodeghiero F; Castaman G; Mariani G; Mannucci PM; de Groot PG; Sixma JJ
    Thromb Haemost; 1990 Oct; 64(2):227-31. PubMed ID: 2125373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluation of a factor VIII concentrate heat-treated to inactivate HTLV-III/LAV viruses. Favourable effects of heating on the von Willebrand factor.
    Mazurier C; de Romeuf C; Parquet-Gernez A; Jorieux S; Goudemand M
    Vox Sang; 1987; 52(4):265-71. PubMed ID: 3114955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease.
    Ver Elst KM; van Vliet HD; Kappers-Klunne MC; Leebeek FW
    Thromb Haemost; 2004 Jul; 92(1):67-74. PubMed ID: 15213847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody.
    Fricke WA; Brinkhous KM; Garris JB; Roberts HR
    Blood; 1985 Sep; 66(3):562-9. PubMed ID: 3927998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers.
    Weiss HJ; Meyer D; Rabinowitz R; Pietu G; Girma JP; Vicic WJ; Rogers J
    N Engl J Med; 1982 Feb; 306(6):326-33. PubMed ID: 6798442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.
    Ruggeri ZM; Pareti FI; Mannucci PM; Ciavarella N; Zimmerman TS
    N Engl J Med; 1980 May; 302(19):1047-51. PubMed ID: 6767976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between bleeding time and platelet adherence to artery subendothelium.
    Sakariassen KS; Bolhuis PA; Blombäck M; Thorell L; Blombäck B; Sixma JJ
    Thromb Haemost; 1984 Oct; 52(2):144-7. PubMed ID: 6441301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat-treated factor VIII/von Willebrand factor concentrate in platelet-type von Willebrand's disease.
    Takahashi H; Tatewaki W; Nagayama R; Hanano M; Tamura M; Yamaguchi T; Takizawa S; Wada K; Shibata A
    Haemostasis; 1987; 17(6):353-60. PubMed ID: 3123334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.